What is Syndax Pharmaceuticals, Inc. (SNDX)?
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer. The company primarily concentrates on epigenetic therapies and immuno-oncology, aiming to address unmet medical needs in oncology. Syndax's research and development efforts include the advancement of drug candidates that target specific molecular pathways involved in tumor growth and immune response modulation. The company collaborates with academic institutions and industry partners to support its clinical programs. Syndax Pharmaceuticals operates within the biotechnology sector and is engaged in the discovery, development, and potential commercialization of innovative cancer treatments. Its pipeline includes compounds designed to enhance the efficacy of existing therapies or provide new options for patients with various types of cancer. The company is headquartered in the United States and contributes to the broader field of oncology drug development through its focus on epigenetic and immune-based therapeutic approaches.
Syndax Pharmaceuticals, Inc. Stock Price Today: Live Overview
The price today is shaped by ongoing intraday activity, with Syndax Pharmaceuticals, Inc. at $24.08. It has fluctuated within the range of $23.29 to $24.12, reflecting a daily move of +1.4831%.
FAQ: Syndax Pharmaceuticals, Inc. (SNDX)
What is the current price of SNDX stock?
The last traded price is $24.08.
Does SNDX pay dividends?
Syndax Pharmaceuticals, Inc. does not pay dividends.
Does SNDX have a formal corporate presence or regional headquarters in the UAE?
Syndax Pharmaceuticals, Inc. does not maintain a regional office or subsidiary in the UAE and operates through partners.
What is SNDX best known for?
Syndax Pharmaceuticals, Inc. is most famous for developing cancer and immunology therapies.
What assets are typically shown together with SNDX?
Commonly shown alongside SNDX: CSPC Pharmaceutical, GSK, Teva Pharma Ind Adr Rep 1
Latest shares articles



